- Home
- REGN vs EOG Comparison
REGN vs EOG Comparison
Compare REGN & EOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- EOG
- Stock Information
- Founded
- REGN 1988
- EOG 1985
- Country
- REGN United States
- EOG United States
- Employees
- REGN N/A
- EOG N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- EOG Oil & Gas Production
- Sector
- REGN Health Care
- EOG Energy
- Exchange
- REGN Nasdaq
- EOG Nasdaq
- Market Cap
- REGN 56.7B
- EOG 60.5B
- IPO Year
- REGN 1991
- EOG N/A
- Fundamental
- Price
- REGN $567.74
- EOG $123.03
- Analyst Decision
- REGN Buy
- EOG Buy
- Analyst Count
- REGN 22
- EOG 22
- Target Price
- REGN $840.95
- EOG $138.05
- AVG Volume (30 Days)
- REGN 987.0K
- EOG 4.1M
- Earning Date
- REGN 08-01-2025
- EOG 08-07-2025
- Dividend Yield
- REGN 0.62%
- EOG 3.17%
- EPS Growth
- REGN 16.49
- EOG N/A
- EPS
- REGN 39.43
- EOG 10.80
- Revenue
- REGN $14,085,700,000.00
- EOG $23,479,000,000.00
- Revenue This Year
- REGN N/A
- EOG N/A
- Revenue Next Year
- REGN $6.77
- EOG $12.57
- P/E Ratio
- REGN $14.40
- EOG $11.40
- Revenue Growth
- REGN 7.52
- EOG N/A
- 52 Week Low
- REGN $476.49
- EOG $102.52
- 52 Week High
- REGN $1,211.20
- EOG $138.18
- Technical
- Relative Strength Index (RSI)
- REGN 63.13
- EOG 56.73
- Support Level
- REGN $532.60
- EOG $119.82
- Resistance Level
- REGN $559.46
- EOG $125.08
- Average True Range (ATR)
- REGN 14.29
- EOG 2.92
- MACD
- REGN 6.52
- EOG -0.22
- Stochastic Oscillator
- REGN 98.82
- EOG 50.87
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About EOG EOG Resources Inc.
EOG Resources is an oil and gas producer with acreage in several US shale plays, primarily in the Permian Basin and the Eagle Ford. At the end of 2024, it reported net proven reserves of 4.7 billion barrels of oil equivalent. Net production averaged roughly 1,062 thousand barrels of oil equivalent per day in 2024 at a ratio of 69% oil and natural gas liquids and 31% natural gas.